1-3 of 3
Victor A. Chow
Close
Sort by
Journal Articles

Megadose 90 Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma

Clinical Trials & Observations
Victor A. Chow, Ryan D. Cassaday, Theodore A. Gooley, Stephen D. Smith, Brenda M. Sandmaier, Damian J. Green, Johnnie J. Orozco, Sherilyn A. Tuazon, Manuela Matesan, Darrell R. Fisher, David G. Maloney, Oliver W. Press, Ajay K. Gopal
Journal: Blood Advances
Blood Adv (2021) 6 (1): 37–45.
https://doi.org/10.1182/bloodadvances.2021005056
Published: 2021
Journal Articles

Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

Clinical Trials & Observations
Jennifer L. Crombie, Loretta J. Nastoupil, Robert Redd, Kevin Tang, Geoffrey Shouse, Alex F. Herrera, Victor A. Chow, Mazyar Shadman, Omar Castaneda Puglianini, Anna Saucier, Caron A. Jacobson, Philippe Armand, Gary Simmons
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3563–3567.
https://doi.org/10.1182/bloodadvances.2021004880
Published: 2021
Journal Articles

Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy

Clinical Trials & Observations
Victor A. Chow, Ajay K. Gopal, Jordan Gauthier, Yolanda D. Tseng, Cameron J. Turtle, David G. Maloney, Mazyar Shadman
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4869–4872.
https://doi.org/10.1182/bloodadvances.2020002292
Published: 2020